Pisit Pitukcheewanont

Pisit Pitukcheewanont
Born	Surin, Thailand
Nationality	Thai
Other names	Dr. Duke
Citizenship	United States, Thailand
Education	Chiang Mai University (MD) Mahidol University (Pediatrics Medicine) The University of Tennessee (Fellowship in Pediatric Endocrinology and Metabolism)
Organization	Human Growth Foundation (Current President)
Known for	Bone and Endocrinology Research
Medical career
Profession	Physician, Professor of Pediatric Medicine & President (HGF)
Institutions	Keck School of Medicine USC, Children's Hospital Los Angeles,
Sub-specialties	Bone Health, Bone Metabolism, and Endocrinology

Pisit Pitukcheewanont, also known as "Dr. Duke"[1] is a Doctor of Medicine, a former professor of Clinical Pediatrics and a philanthropist.[2] Currently, he is an adjunct professor of Clinical Pediatrics[3] at Keck School of Medicine of the University of Southern California, the president of a nonprofit organization, The Human Growth Foundation[2] and Senior Vice President of Global Clinical Development and Medical Affairs Lumos Pharmacy.[4]

Biography

Pisit Pitukcheewanont ("Dr. Duke") was born in Surin, Thailand.^[citation needed] He received his early education from Triam Udom Suksa, Bangkok, Thailand.^[citation needed] He attended Chiang Mai University, Chiang Mai, and completed his doctorate thesis M.D.,^[citation needed] followed by a residency in Pediatrics at the department of pediatrics Faculty of Medicine Chiang Mai University, a Fellowship of Pediatric Endocrinology, and Metabolism at Siriraj Hospital, Faculty of Medicine, Mahidol University, Bangkok, Thailand.^[citation needed]

He moved to the United States in 1994 and completed a second Fellowship of Clinical and Research at the Division of Endocrinology, Metabolism, and Nutrition, Department of Pediatrics, University of Tennessee Medical Center, Knoxville, TN.[5] He then completed a second residency in Pediatrics (PL-3)[6] at University of Tennessee, LeBonheur Children’s Medical Center, Memphis, TN.[1]

After settling in Los Angeles, CA, he went rapidly through the academic hierarchy steps from assistant professor to full professor of Clinical Pediatrics at University of Southern California, Keck School of Medicine.[7] In addition to his professorship at USC, earlier he was senior investigator, Clinical Director of Pediatric Bone Program and Co-Director of Pediatric Endocrine Fellowship and Training Program Program at Keck School of Medicine.[1] He was also a practicing pediatric endocrinologist at the Children's Hospital Los Angeles (1998 to 2018) and was the Executive Board of Director for Thai-Americans Physicians Foundation (2008 to 2011).[8]

Research

Pitukcheewanont's clinical and research interests focus on pediatric endocrinology (especially as it relates to growth and bone health and bone development), the pathogenesis, prevention, and treatment of childhood osteoporosis, and metabolic bone disorders in pediatric patients. He has participated in several major clinical trials related to growth and bone disorders and has over 70 publications in peer-reviewed and non-peer-reviewed scientific papers. His recent publications have been concerned with disparities resulting from various methods of bone density measurement and pediatric bone disorders.

Honors

1980 "American Field Service (AFS): Scholarship to the United States",1984 "Scholarship to Fukui Medical School, University of Fukui, Fukui, Japan",1985-1987 "The Leader of Institute of Foreign Medical Affairs at Faculty of Medicine, Chiang Mai University",1992-1993 "Fellowship Grant in Pediatric Endocrinology and Metabolism, University of Tennessee Medical Center, Knoxville, TN, 1995 "The Lawson Wilkins Pediatric Endocrine Society Travel Grant Award, 2000-2002 "Mentor Junior Faculty Academic Career Development Award, Keck School of Medicine, 2003-Present "Best Doctors In America, 2007-Present", 2007–Present "America’s Top Pediatricians", 2008 "Thai American Physicians Foundation (TAPF) Medical Research Award", 2008 "Thai-American Visiting Professor Award", 2008–Present "Southern California Super Doctors" 2008–Present "President of Human Growth Foundation" 2011 - present "Madison’s Who’s Who in Medicine", 2017–present "Member of Society of Pediatric Research (SPR) Skirball Mentorship Award".^[citation needed]

Publications

He has a substantial record of scholarly publications, with over 70 scientific papers to his credit. He has also served as the editor of multiple books, publishing in clinical pediatrics, bone, endocrinology, and metabolic medicine.

• Briot, Karine; Portale, Anthony A; Brandi, Maria Luisa; Carpenter, Thomas O; Cheong, Hae Ii; Cohen-Solal, Martine; Crowley, Rachel K; Eastell, Richard; Imanishi, Yasuo; Ing, Steven; Insogna, Karl; Ito, Nobuaki; Jan de Beur, Suzanne; Javaid, Muhammad K; Kamenicky, Peter; Keen, Richard; Kubota, Takuo; Lachmann, Robin H; Perwad, Farzana; Pitukcheewanont, Pisit; Ralston, Stuart H; Takeuchi, Yasuhiro; Tanaka, Hiroyuki; Weber, Thomas J; Yoo, Han-Wook; Nixon, Annabel; Nixon, Mark; Sun, Wei; Williams, Angela; Imel, Erik A (September 2021). "Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension". RMD Open. 7 (3): e001714. doi:10.1136/rmdopen-2021-001714. PMC 8458321. PMID 34548383.
• Kaplowitz, Paul B; Manjelievskaia, Janna; Lopez-Gonzalez, Lorena; Marrow, Cynthia D; Pitukcheewanont, Pisit; Smith, Alden (3 May 2021). "Economic Burden of Growth Hormone Deficiency in a US Pediatric Population". Journal of the Endocrine Society. 5 (Supplement_1): A675. doi:10.1210/jendso/bvab048.1376.
• Padidela, Raja; Whyte, Michael P.; Glorieux, Francis H.; Munns, Craig F.; Ward, Leanne M.; Nilsson, Ola; Portale, Anthony A.; Simmons, Jill H.; Namba, Noriyuki; Cheong, Hae Il; Pitukcheewanont, Pisit; Sochett, Etienne; Högler, Wolfgang; Muroya, Koji; Tanaka, Hiroyuki; Gottesman, Gary S.; Biggin, Andrew; Perwad, Farzana; Williams, Angela; Nixon, Annabel; Sun, Wei; Chen, Angel; Skrinar, Alison; Imel, Erik A. (May 2021). "Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia". Calcified Tissue International. 108 (5): 622–633. doi:10.1007/s00223-020-00797-x. PMID 33484279.
• Kaplowitz, Paul; Manjelievskaia, Janna; Lopez-Gonzalez, Lorena; Morrow, Cynthia D; Pitukcheewanont, Pisit; Smith, Alden (August 2021). "Economic burden of growth hormone deficiency in a US pediatric population". Journal of Managed Care & Specialty Pharmacy. 27 (8): 1118–1128. doi:10.18553/jmcp.2021.21030.
• Kamenický, Peter; Portale, Anthony A.; Carpenter, Tom; Briot, Karine; Imel, Erik A.; Weber, Thomas; Pitukcheewanont, Pisit; Cheong, Hae Il; de Beur, Suzanne Jan; Imanishi, Yasuo; Ito, Nobuaki; Lachmann, Robin; Tanaka, Hiroyuki; Perwad, Farzana; Zhang, Lin; Skrinar, Alison; Rees, Linda; Insogna, Karl L. (October 2020). "Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial". Bone Reports. 13: 100654. doi:10.1016/j.bonr.2020.100654.
• Perwad, Farzana; Portale, Anthony A; Carpenter, Thomas O; Briot, Karine; Imel, Erik Allen; Kamenicky, Peter; Weber, Thomas Joseph; Pitukcheewanont, Pisit; Cheong, Hae Il; De Beur, Suzanne Marie Jan; Imanishi, Yasuo; Ito, Nobuaki; Lachmann, Robin; Tanaka, Hiroyuki; Zhang, Lin; Skrinar, Alison; Rees, Linda; Insogna, Karl Leonard (8 May 2020). "OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial". Journal of the Endocrine Society. 4 (Supplement_1). doi:10.1210/jendso/bvaa046.147.
• Ea, Imel; Fh, Glorieux; Mp, Whyte; Cf, Munns; Lm, Ward; O, Nilsson; Jh, Simmons; R, Padidela; N, Namba; Hi, Cheong; P, Pitukcheewanont; E, Sochett; W, Hogler; K, Muroya; H, Tanaka; Gs, Gottesman; A, Biggin; F, Perwad; M, Mao; Cy, Chen; A, Skrinar; J, San Martin; Aa, Portale (12 September 2019). "Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial". Yearbook of Paediatric Endocrinology. doi:10.1530/ey.16.5.8. hdl:1805/24198.
• Nguyen, Antoine T; Pitukcheewanont, Pisit; Ryabets-Lienhard, Anna (8 May 2020). "SUN-LB66 Oral Risedronate Treatment in Children With Osteogenesis Imperfecta". Journal of the Endocrine Society. 4 (Supplement_1). doi:10.1210/jendso/bvaa046.2159.
• Portale, Anthony A.; Carpenter, Thomas O.; Brandi, Maria Luisa; Briot, Karine; Cheong, Hae II; Cohen-Solal, Martine; Crowley, Rachel; Jan De Beur, Suzanne; Eastell, Richard; Imanishi, Yasuo; Imel, Erik A.; Ing, Steven; Ito, Nobuaki; Javaid, Muhammad; Kamenicky, Peter; Keen, Richard; Kubota, Takuo; Lachmann, Robin; Perwad, Farzana; Pitukcheewanont, Pisit; Ralston, Stuart H.; Takeuchi, Yasuhiro; Tanaka, Hiroyuki; Weber, Thomas J.; Yoo, Han-Wook; Zhang, Lin; Theodore-Oklota, Christina; Mealiffe, Matt; San Martin, Javier; Insogna, Karl (September 2019). "Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period". Calcified Tissue International. 105 (3): 271–284. doi:10.1007/s00223-019-00568-3.

References

1. "Pisit Pitukcheewanont, MD". Children’s Hospital Los Angeles. 2022-01-11. Retrieved 2023-01-21.
2. "Our Team". HGF. Retrieved 2023-01-21.
3. "Pediatrics – Childrens Hospital of Los Angeles – Departments Directory". departmentsdirectory.usc.edu.
4. "Our Team | Lumos Pharma". lumos-pharma.com. 2019-12-17. Retrieved 2023-01-21.
5. "Pisit "Duke" Pitukcheewanont # Pisit "Duke" Pitukcheewanont | Lumos Pharma". lumos-pharma.com. 2023-02-24. Retrieved 2025-01-28.
6. "2008 Awards | Thai-American Physicians Foundation". Retrieved 2023-01-26.
7. "Dr. Pisit Pitukcheewanont, MD – Los Angeles, CA | Pediatric Endocrinology on Doximity". Doximity. Retrieved 2025-01-28.
8. "TAPF Medical Research Award". Children’s Hospital Los Angeles. 2015-11-11. Retrieved 2022-12-27.